Kalliokoski A - Search Results

1

Effects of gemfibrozil and atorvastatin on the pharmacokinetics of repaglinide in relation to SLCO1B1 polymorphism.

Kalliokoski A, Backman JT, Kurkinen KJ, Neuvonen PJ, Niemi M. Kalliokoski A, et al. Clin Pharmacol Ther. 2008 Oct;84(4):488-96. doi: 10.1038/clpt.2008.74. Clin Pharmacol Ther. 2008. PMID: 19238654 Clinical Trial.

2

SLCO1B1 polymorphism and oral antidiabetic drugs.

Kalliokoski A, Neuvonen PJ, Niemi M. Kalliokoski A, et al. Basic Clin Pharmacol Toxicol. 2010 Oct;107(4):775-81. doi: 10.1111/j.1742-7843.2010.00581.x. Basic Clin Pharmacol Toxicol. 2010. PMID: 20406215 Free article. Review.

3

Effect of SLCO1B1 polymorphism on the plasma concentrations of bile acids and bile acid synthesis marker in humans.

Xiang X, Han Y, Neuvonen M, Pasanen MK, Kalliokoski A, Backman JT, Laitila J, Neuvonen PJ, Niemi M. Xiang X, et al. Among authors: kalliokoski a. Pharmacogenet Genomics. 2009 Jun;19(6):447-57. doi: 10.1097/FPC.0b013e32832bcf7b. Pharmacogenet Genomics. 2009. PMID: 19387419

4

Effects of the SLCO1B1*1B haplotype on the pharmacokinetics and pharmacodynamics of repaglinide and nateglinide.

Kalliokoski A, Backman JT, Neuvonen PJ, Niemi M. Kalliokoski A, et al. Pharmacogenet Genomics. 2008 Nov;18(11):937-42. doi: 10.1097/FPC.0b013e32830d733e. Pharmacogenet Genomics. 2008. PMID: 18854776 Clinical Trial.

5

The effect of SLCO1B1 polymorphism on repaglinide pharmacokinetics persists over a wide dose range.

Kalliokoski A, Neuvonen M, Neuvonen PJ, Niemi M. Kalliokoski A, et al. Br J Clin Pharmacol. 2008 Dec;66(6):818-25. doi: 10.1111/j.1365-2125.2008.03287.x. Epub 2008 Sep 23. Br J Clin Pharmacol. 2008. PMID: 18823304 Free PMC article.

6

No significant effect of SLCO1B1 polymorphism on the pharmacokinetics of rosiglitazone and pioglitazone.

Kalliokoski A, Neuvonen M, Neuvonen PJ, Niemi M. Kalliokoski A, et al. Br J Clin Pharmacol. 2008 Jan;65(1):78-86. doi: 10.1111/j.1365-2125.2007.02986.x. Epub 2007 Jul 17. Br J Clin Pharmacol. 2008. PMID: 17635496 Free PMC article. Clinical Trial.

7

Different effects of SLCO1B1 polymorphism on the pharmacokinetics and pharmacodynamics of repaglinide and nateglinide.

Kalliokoski A, Neuvonen M, Neuvonen PJ, Niemi M. Kalliokoski A, et al. J Clin Pharmacol. 2008 Mar;48(3):311-21. doi: 10.1177/0091270007311569. Epub 2008 Jan 10. J Clin Pharmacol. 2008. PMID: 18187595 Clinical Trial.

8

Impact of OATP transporters on pharmacokinetics.

Kalliokoski A, Niemi M. Kalliokoski A, et al. Br J Pharmacol. 2009 Oct;158(3):693-705. doi: 10.1111/j.1476-5381.2009.00430.x. Epub 2009 Sep 25. Br J Pharmacol. 2009. PMID: 19785645 Free PMC article. Review.

9

The effect of gemfibrozil on repaglinide pharmacokinetics persists for at least 12 h after the dose: evidence for mechanism-based inhibition of CYP2C8 in vivo.

Tornio A, Niemi M, Neuvonen M, Laitila J, Kalliokoski A, Neuvonen PJ, Backman JT. Tornio A, et al. Among authors: kalliokoski a. Clin Pharmacol Ther. 2008 Sep;84(3):403-11. doi: 10.1038/clpt.2008.34. Epub 2008 Mar 26. Clin Pharmacol Ther. 2008. PMID: 18388877 Clinical Trial.

10

Diffusion tensor imaging of chronic right cerebral hemisphere infarctions.

Jason E, Dastidar P, Kalliokoski A, Luukkaala T, Soimakallio S. Jason E, et al. Among authors: kalliokoski a. J Neuroimaging. 2011 Oct;21(4):325-31. doi: 10.1111/j.1552-6569.2010.00513.x. Epub 2010 Oct 26. J Neuroimaging. 2011. PMID: 20977525

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results